

Article

# Synthesis and Antimicrobial Evaluation of a New Series of Heterocyclic Systems Bearing a Benzosuberone Scaffold

Osama I. Abd El-Salam<sup>1</sup>, Ali S. Alsayed<sup>2</sup>, Korany A. Ali<sup>1</sup>, Ahmed A. Abd Elwahab<sup>1</sup>, Abd El-Galil E. Amr<sup>3,\*</sup> and Hassan M. Awad<sup>4,5</sup>

Received: 11 September 2015 ; Accepted: 4 November 2015 ; Published: 16 November 2015  
Academic Editor: Wim Dehaen

<sup>1</sup> Applied Organic Chemistry Department, National Research Centre, Dokki, Giza 12622, Egypt; osielsalam@gmail.com (O.I.A.E.-S.); kornykhilil@gmail.com (K.A.A.); ahmed\_abdelsalam@hotmail.com (A.A.A.E.)

<sup>2</sup> Chemistry Department, Al-Azhar University, Nasr City, Cairo 1435, Egypt; ali.sief1980@hotmail.com

<sup>3</sup> Department of Pharmaceutical Chemistry, Drug Exploration & Development Chair, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

<sup>4</sup> Chemistry of Natural and Microbial Products Department, Pharmaceutical Industries Division, National Research Centre, 33 El Buhouth St. (Former El Tahrir St.), Dokki, Giza 12622, Egypt; awadmhassan@yahoo.com

<sup>5</sup> Deanship of Preparatory Year, Al Jouf University, AL Jouf, Skaka 2014, Saudi Arabia

\* Correspondence: aeamr1963@yahoo.com or aamr@ksu.edu.sa; Tel.: +966-565-148-750

**Abstract:** A series of novel benzosuberone derivatives were synthesized and evaluated as antimicrobial agents by using substituted benzosuberone derivatives **1a,b** as starting materials. Treatment of **1a,b** with phenyl isothiocyanate in dimethylformamide was followed by treatment with cold HCl solution to afford the thioamides **4a,b**, which was reacted with methyl iodide to obtain methylated products **5a,b**. Cyclocondensation of **4a,b** with chloroacetone **6** and phenacyl chloride **7** gave the corresponding thiophene derivatives **9a–c**. Reaction of **4a,b** with *C*-acetyl-*N*-arylhydrazonoyl chlorides **14a** and **14b** in boiling EtOH in the presence of triethylamine, afforded the corresponding 1,3,4-thiadiazoline derivatives **16a–d**. The thioamides **4a,b** were reacted with *C*-ethoxycarbonyl-*N*-arylhydrazonoyl chlorides **18a,b** which afforded 1,3,4-thiadiazoline derivatives **19a–d**. The benzosuberones **1a,b** were treated with 3-mercaptopropanoic acid to give compounds **21a,b**, which were cyclized to tricyclic thiopyran-4(5*H*)-one derivatives **22a,b**. The latter compounds **22a,b** were reacted with 3-mercaptopropanoic acid to give compounds **23a,b**, which were cyclized tetracyclic ring systems **24a,b**. Finally, compounds **24a,b** were oxidized using hydrogen peroxide under reflux conditions to afford the oxidized form of the novel tetracyclic heterogeneous ring systems **25a,b**. The newly synthesized compounds were screened for antimicrobial activities. The structures of new compounds were characterized by <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, IR, and EI-MS.

**Keywords:** benzosuberone; nitro-benzosuberone; thioamide; thiophene; thiadiazole; antimicrobial activity

## 1. Introduction


Thiazolopyrimidine derivatives were studied as potential drug candidates with biological activities [1]. In a previous work, we reported that certain of our newly substituted heterocyclic compounds exhibited androgen receptor antagonists and anticancer activities [2,3]. Also, substituted and condensed cycloalkanones derivatives are of special interest for the preparation of potentially

bioactive compounds as they possess anti-inflammatory, anti-convulsant, anti-pyretic, anti-tumor, and anti-ulcer activities [4]. Benzosuberone moiety is the main scaffold in tricyclic antidepressant drugs such as noxiptiline and amitriptyline (the analogues of imipramine), which mostly affect the central nervous systems [5,6]. On the other hand, heterocyclic sulfur compounds are of special interest in modern medicinal chemistry. For example, thiophene and thiadiazole derivatives are a well-known class of biologically active basic compounds for a large number of new drugs [7–9]. In view of these observations and in continuation of our current interest in the synthesis of poly-substituted heterocycles for biological evaluations [10–14], the present work was planned to prepare some new benzosuberone derivatives bearing thiadiazole and thiophene moiety, in addition to synthesis of new tricyclic and tetracyclic compounds bearing the benzosuberone scaffold. The newly synthesized compounds were investigated as antimicrobial agents.

## 2. Results and Discussion

### 2.1. Chemistry


Thioamide and thioanilide intermediates are considered to be a category of versatile intermediates that provide building blocks in the synthesis of poly-substituted thiophene and thiadiazole derivatives [15,16]. Preparation of benzosuberone derivatives substituted with thioamide and thioanilide was achieved by the treatment of the benzosuberone derivatives **1a,b** with phenyl isothiocyanate in dimethylformamide, in the presence of potassium hydroxide, followed by treatment with cold HCl solution to afford the thioamide derivatives **4a,b** with 81% and 79% yields, respectively (Scheme 1). The  $^1\text{H-NMR}$  spectrum of the thioamide **4a** as an example, revealed the presence of multiple signals at 1.90 ppm and two triplet signals 2.41–3.20 ppm characteristic for  $3\text{CH}_2$  protons, in addition to a broad signal at 11.50 ppm due to NH proton. The mass spectrum of compound **4a** revealed a peak at  $m/z$  295 corresponding to its molecular ion peak. Treatment of the thioamide derivatives **4a,b** with methyl iodide in EtONa solution afforded the methylated products **5a,b** (Scheme 1). The  $^1\text{H-NMR}$  spectrum of compound **5a** displayed a new singlet signal at 3.08 ppm characteristic for S-methyl group.



**Scheme 1.** Synthetic routes for compounds **4a,b** and **5a,b**.


Cyclocondensation of the thioamide derivatives **4a** and **4b** with chloroacetone **6** and phenacyl chloride **7** in refluxing EtOH, in the presence of a catalytic amount of triethylamine furnished, in each case, was only one isolated product. The identities of the isolated products were assigned as the thiophene derivatives **9a–c** rather than the isomeric 1,3-thiazoles **10** (*Method A*, Scheme 2), on the basis of their spectral data. The IR spectrum of compound **9b**, as an example of the synthesized compounds, showed the presence of NH and carbonyl bands at 3428 and 1654  $\text{cm}^{-1}$ , respectively.

Moreover, the  $^1\text{H-NMR}$  spectrum of compound **9b**, revealed multiplets at 1.72 and 2.35–2.59 ppm corresponding to  $3\text{CH}_2$  groups, in addition to signals at 3.30 and 9.53 ppm corresponding to  $\text{CH}_3$  and  $\text{NH}$  protons, respectively. Compound **9c** was also prepared using thioamide derivative **4a** and phenacyl chloride **7b** in DMF in the presence of potassium carbonate at room temperature (Method B, Scheme 2). The product **9c** from the later method was identical in all respects with the previously obtained authentic sample **9c**.




**Scheme 2.** Synthetic routes for compounds **9a–c**.

Further evidence for the proposed structure of compound **9a** was obtained by an independent synthesis via treatment of thioamide derivative **4a** with 3-chloroacetylacetone in refluxing EtOH, in the presence of a catalytic amount of triethylamine. The obtained product **9a** identical in all respects (mp, TLC, and spectra) with that obtained from the reaction of the thioamide derivative **4a** with chloroacetone. A reasonable mechanism of the latter reaction is outlined in Scheme 3, the addition of the haloketone to **4a** with the elimination of HCl gave **11** followed by intramolecular cyclization to give **12**, which under the effect of hydronium ion gave **13** and elimination of acetic acid gave **9a**.



**Scheme 3.** Mechanism of formation compound **9a**.


We have investigated the behavior of the thioamide derivatives **4a,b** toward hydrazoneyl halide derivatives to prompt our synthetic strategy toward new heterocyclic systems attached to the benzo-suberone scaffold. Thus, treatment of the thioamide derivatives **4a** and **4b** with *C*-acetyl-*N*-arylhydrazoneyl chlorides **14a** and **14b** in boiling EtOH in the presences of triethylamine, afforded in each case only one isolated product. The identities of the isolated products were assigned as the 1,3,4-thiadiazoline derivatives **16a–d** rather than the arylhydrazone-thiazole derivative **17** on the basis of their spectroscopic data (Scheme 4). For example, compound **16c** showed characteristic IR bands at 1671, 1653  $\text{cm}^{-1}$  due to two carbonyl groups. The  $^1\text{H-NMR}$  spectrum of **16c** revealed multiplets at 1.53, 2.38–2.46 ppm due to the protons of  $3\text{CH}_2$  groups and signal at 3.43 ppm due to the acetyl protons. In addition, its mass spectrum revealed a peak at  $m/z$  380 corresponding to its molecular ion peak.




**Scheme 4.** Synthetic routes for compounds **16a–d**.

In a similar manner, the thioamides **4a** and **4b** were reacted with *C*-ethoxycarbonyl-*N*-arylhydrazoneyl chlorides **18a** and **18b** under the same reaction condition and afforded 1,3,4-thiadiazoline derivatives **19a–d** rather than the thiazole-4-one derivative **20** on the basis of their spectroscopic data (Scheme 5). For example, compound **19a** showed characteristic IR bands at 1718, 1675  $\text{cm}^{-1}$  due to  $2\text{C}=\text{O}$  groups. The  $^1\text{H-NMR}$  spectrum of **19a** was revealed triplet and quartet signals at 1.71 and 4.20 because of methyl and methylene of the ester group, in addition to multiplets in the region 2.36–2.8 ppm due to the protons of  $3\text{CH}_2$  groups. The mass spectrum of compound **19a** revealed a peak at  $m/z$  392 corresponding to its molecular ion.

The reaction of **1a,b** with 3-mercaptopropanoic acid in refluxing benzene, in the presence of 4-toluenesulfonic acid (PTSA), results in compounds **21a,b** which undergo intermolecular cyclization under reflux temperature using phosphorus pentoxide to afford the novel tricyclic thiopyran-4(5*H*)-one derivatives **22a,b** (Scheme 6). The structures of the latter products were established on the basis of their elemental analysis and spectral data.



Scheme 5. Synthetic route for compounds 19a–d.




Scheme 6. Synthetic routes for compounds 21a,b and 22a,b.

Treatment of the thiopyran-4(5H)-one derivatives **22a,b** in step 1 with 3-mercaptopropanoic acid in refluxing benzene, in the presence of 4-toluenesulfonic acid (PTSA), afford the non-isolated intermediates **23a,b** that undergo intramolecular cyclization under reflux temperature using phosphorus pentoxide to afford the novel tetracyclic ring systems **24a,b** (Scheme 7). The structures of compounds **24a,b** were established on the basis of their elemental analysis and spectral data. The IR spectrum of compound **24a** showed the presence of the carbonyl band at 1692 cm<sup>-1</sup>. The <sup>1</sup>H-NMR spectrum of **24** revealed multiplets at 2.25–2.50 and 3.25–3.38 ppm corresponding to 5CH<sub>2</sub> groups, in addition to the signal at 3.73 ppm corresponding to CH<sub>2</sub> of the thiopyran protons.

The later products were oxidized using hydrogen peroxide under reflux condition to afford the oxidized form of the novel tetracyclic derivatives **25a,b** (Scheme 7).

Due to the oxidation of compounds **24a,b** to compounds **25a,b**, the carbonyl band in the IR spectrum of compound **25a** for example shifted to 1695 cm<sup>-1</sup>. The <sup>1</sup>H-NMR spectrum of compound **25a** revealed multiplets near 1.76, 2.15, 2.63 and 3.27 ppm corresponding to 5 CH<sub>2</sub> groups, in addition to signal at 2.63 ppm corresponding to CH<sub>2</sub> of the dioxothiopyran protons.



Scheme 7. Synthetic routes for compounds 24 and 25.

## 2.2. Antimicrobial Screening

The *in vitro* antimicrobial activity of the synthesized compounds was screened against three gram-positive bacteria (*Bacillus subtilis*, *Staphylococcus aureus* and *Enterococcus faecalis*) and three gram-negative bacteria (*Escherichia coli*, *Pseudomonas aeruginosa* and *Proteus* sp.), yeast (*Candida albicans*) and filamentous fungi (*Aspergillus niger* and *A. flavus*). The tested products have shown a strong to moderate effect against most of the tested pathogens.

Most of the compounds showed a moderate inhibitory effect against Gram-positive bacteria (*Bacillus subtilis*, *Staphylococcus aureus* and *Enterococcus faecalis*) except compounds **25b** and **22a**, which showed strong inhibition effect in comparison with the standard antibiotics used (Table 1). On the other hand, five compounds **25b**, **9c**, **19b**, **21b** and **5a** showed a strong inhibitory effect (15–25 mm) against *Escherichia coli*, as an example of Gram-negative bacteria. While the others showed a weak to a moderate inhibition effect against *Pseudomonas aeruginosa*, *Proteus* sp. The antifungal activities are presented in Table 1. In case of unicellular fungi most of the compounds showed a strong antifungal effect against *Candida albicans*. These compounds are **22a**, **25b**, **21a**, **9c** and **19b** while the other compounds were characterized by moderate antifungal effect. In the case of filamentous fungi, compounds **22a**, **25b**, **4b**, **5a**, **5b**, **9c**, **19d**, **22b** and **24a** have a higher antifungal effect against *Aspergillus niger* and a moderate activity against *A. flavus* in comparison with the antifungal standard antibiotic (Neomycin) used in this study. Finally, the demonstration of the activity of compound **25b** against gram-positive bacteria, gram-negative bacteria, and fungi is an indication that this compound can be used in the treatment of the tested pathogens due to its broad spectrum effect.

The structure-activity relationships (SAR) of these synthesized compounds (Tetracyclic derivatives) may be due to their ability for inhibiting the cell growth by inhibiting the protein synthesis [17,18].

The minimum inhibitory concentration (MIC) of the synthesized compounds is presented in the Table 2. The MIC varied from 50 to 500 µg/mL based on the tested compounds. The MIC of the compound **25b** was 50, 50, 75 and 100 µg/mL against tested pathogens *E. coli*, *C. albicans*, *B. subtilis* and *A. niger*. On the other hand, the MIC of the compound **22a** was 100 µg/mL against *Bacillus subtilis*, while the MIC of the compound **9c** was 200 µg/mL against *Bacillus subtilis*. Finally, we can interpret that some of samples have strongest antifungal and antibacterial activities. The demonstration of the activity against gram-positive bacteria, gram-negative bacteria, and fungi is

an indication that the compounds have a broad spectrum effect. A few of the test compounds possessed a broad spectrum of activity having MIC values ranging from 50 to 200 µg/mL.

**Table 1.** Antimicrobial activity of compounds at 10 mg/mL.

Comp. No.	Bacteria						Fungi		
	G + ve			G – ve			unicellular	filamentous	
	<i>B. subtilis</i>	<i>S. aureus</i>	<i>Ent. faecalis</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>Proteus sp.</i>	<i>C. albicans</i>	<i>A. niger</i>	<i>A. flavus</i>
4a	17	17	14	17	14	15	15	12	11
4b	15	15	12	15	12	13	00	20	18
5a	00	18	15	18	15	14	15	20	19
5b	00	12	11	12	11	12	15	20	15
9a	12	00	00	00	00	00	00	00	00
9b	12	00	00	00	00	00	00	00	00
9c	22	20	17	20	18	17	17	20	16
16a	20	16	14	16	14	15	00	00	00
16b	12	00	00	00	00	00	00	00	00
16c	15	15	13	15	12	13	00	00	00
16d	14	13	12	13	12	11	00	00	00
19a	12	00	00	00	00	00	00	00	00
19b	22	20	17	20	17	18	17	00	00
19c	12	00	00	00	00	00	00	00	00
19d	20	17	14	17	14	15	00	20	17
21a	17	15	13	15	12	13	20	00	00
21b	14	20	18	20	15	17	00	00	00
22a	25	00	00	00	00	00	30	40	20
22b	15	00	00	00	00	00	15	18	16
24a	15	00	00	00	00	00	15	18	15
24b	12	00	00	00	00	00	15	00	00
25a	17	00	00	00	00	00	00	00	00
25b	27	25	19	25	19	20	25	29	20
S* =10 µg	14	00	00	00	00	00	12	00	00
TE* =30 µg	10	00	00	00	00	00	23	00	00
N* =30 µg	00	00	00	00	00	00	00	16	14
T* =30 µg	30	00	00	00	00	00	00	00	00

\* S = Streptomycin; TE = Tetracycline; N = Neomycin and T = Oxytetracycline.

**Table 2.** Minimum inhibitory concentration (MIC) of different compounds against of tested pathogens.

Comp. No.	Inhibition Zone Diameters (mm)				MIC (µg/mL)			
	<i>B. subtilis</i>	<i>E. coli</i>	<i>C. albicans</i>	<i>A. niger</i>	<i>B. subtilis</i>	<i>E. coli</i>	<i>C. albicans</i>	<i>A. niger</i>
25b	11	11	11	11	75	50	50	100
22a	11	-	-	-	100	-	-	-
9c	11	-	-	-	200	-	-	-

### 3. Experimental Section

#### 3.1. Chemistry

All melting points were measured on a Gallenkamp melting point apparatus (Weiss Gallenkamp, London, UK). The infrared spectra were recorded in potassium bromide disks on a Pye Unicam SP 3300 and Shimadzu FT IR 8101 PC infrared spectrophotometers (Pye Unicam Ltd. Cambridge, UK and Shimadzu, Tokyo, Japan, respectively). The NMR spectra were recorded on a Varian Mercury VX-300 NMR spectrometer (Varian, Palo Alto, CA, USA). <sup>1</sup>H spectra were run at 300 MHz and <sup>13</sup>C spectra were run at 75.46 MHz in deuterated chloroform (CDCl<sub>3</sub>) or dimethyl sulfoxide (DMSO-*d*<sub>6</sub>). (Sigma-Aldrich, St. Louis, MO, USA). Chemical shifts are given in parts per million and were related to that of the solvent. Mass spectra were recorded on a Shimadzu GCMS-QP 1000 EX mass spectrometer (Shimadzu, Tokyo, Japan) at 70 eV. Elemental analyses were carried out at the Micro-analytical Centre of Cairo University, Giza, Egypt and recorded on Elementar-Vario EL (ELTRA GmbH, Haan, Germany) automatic analyzer. Compounds **1b**, **14a–c** and **18a–c** were prepared by following the reported procedures in the literature [19–22]. The *in vitro* antimicrobial screening was performed by Chemistry of Natural and Microbial Products Dept., National Research Centre, Cairo-12622, Cairo, Egypt.

### 3.1.1. Preparation of the Thioamide Derivatives **4a,b**

A solution of finely ground KOH (0.12 g, 2 mmol) and benzosuberone derivatives **1a,b** (2 mmol) in DMF (10 mL), was stirred for 2 h. Phenyl isothiocyanate (0.27 g, 10.0 mmol) was then added drop-wise and the mixture was stirred for 10–12 h. The mixture was poured onto cold water acidified with 1N HCl. The solid product obtained was filtered off, washed with water, dried, and finally recrystallized with the proper solvent to afford the thioamidederivatives **4a,b**.

*6,7,8,9-Tetrahydro-6-(mercapto(phenylamino)methylene)benzo[7]annulen-5-one 4a.* Yield: (0.24 g, 81%); mp: 185–187 °C; as a pale yellow crystals (MeOH). IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  3430 (NH), 1637 (C=O).  $^1\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  1.90 (m, 2H,  $\text{CH}_2$ ), 2.41–3.20 (m, 4H,  $2\text{CH}_2$ ), 6.99–7.90 (m, 9H, Ar-H), 8.50 (br s, 1H, NH,  $\text{D}_2\text{O}$  exchangeable). MS  $m/z$  (%): 296  $[\text{M} + 1]^+$  (5), 295  $[\text{M}]^+$  (25), 219 (10), 205 (40), 160 (30), 92 (100), 77 (50). Anal. Calcd. for  $\text{C}_{18}\text{H}_{17}\text{NOS}$  (295.40): C, 73.19; H, 5.80; N, 4.74; S, 10.85. Found: C, 73.44; H, 5.89; N, 4.62; S, 10.79.

*6,7,8,9-Tetrahydro-6-(mercapto(phenylamino)methylene)-3-nitrobenzo[7]annulen-5-one 4b.* Yield: (0.27 g, 79%); mp: 215–217 °C; yellow crystals (EtOH). IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  3433 (NH), 1663 (C=O).  $^1\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  1.94–3.30 (m, 6H,  $3\text{CH}_2$ ), 7.01–8.27 (m, 8H, Ar-H), 9.20 (br s, 1H, NH,  $\text{D}_2\text{O}$  exchangeable).  $^{13}\text{C-NMR}$  (DMSO- $d_6$ ):  $\delta$  25.41, 25.60, 39.90, 115.68, 119.98, 120.39, 124.39, 129.51, 130.88, 138.88, 139.05, 142.92, 147.15, 155.41, 189.93. MS  $m/z$  (%): 341  $[\text{M} + 1]^+$  (3), 340  $[\text{M}]^+$  (15), 338 (100), 262 (35), 205 (60). Anal. Calcd. for  $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}_3\text{S}$  (340.40): C, 63.51; H, 4.74; N, 8.23; S, 9.42. Found: C, 63.44; H, 4.69; N, 7.97; S, 9.48.

### 3.1.2. General Procedure for Preparation of the S-Methylated Thioamide Derivatives **5a,b**

To a stirred solution of the thioamide derivatives **4a,b** (1 mmol) and potassium carbonate (0.14 g, 1 mmol) in DMF (10 mL), iodomethane (0.28 g, 2 mmol) was added and stirring was continued for another 12 h. The mixture was poured onto crushed ice and the solid product obtained was filtered off, washed with water, dried, and finally recrystallized from the proper solvent to afford colorless crystals of compounds **5a,b**.

*6,7,8,9-Tetrahydro-6-(methylthio(phenylamino)methylene)benzo[7]annulen-5-one 5a.* Yield: (0.26 g, 84%); mp: 195–197 °C; buff powder (MeOH/dioxan). IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  3400(NH), 1674 (C=O).  $^1\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  1.77–2.51 (m, 6H,  $3\text{CH}_2$ ), 3.08 (s, 3H,  $\text{CH}_3$ ), 6.86–7.79 (m, 9H, Ar-H), 8.31 (br s, 1H, NH,  $\text{D}_2\text{O}$  exchangeable). MS  $m/z$  (%): 310  $[\text{M} + 1]^+$  (8), 309  $[\text{M}]^+$  (45), 261 (30), 217 (20), 115 (70), 91 (50), 77 (100). Anal. Calcd. for  $\text{C}_{19}\text{H}_{19}\text{NOS}$  (309.43): C, 73.75; H, 6.19; N, 4.53; S, 10.36. Found: C, 73.52; H, 6.10; N, 4.62; S, 10.44.

*6,7,8,9-Tetrahydro-6-(methylthio(phenylamino)methylene)-3-nitrobenzo[7]annulen-5-one 5b.* Yield: (0.31 g, 84%); mp: 225–227 °C; pale yellow crystals (EtOH/DMF). IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  3430 (NH), 1664 (C=O).  $^1\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  1.77 (m, 2H,  $\text{CH}_2$ ), 2.30–2.51 (m, 4H,  $2\text{CH}_2$ ), 3.30 (s, 3H,  $\text{CH}_3$ ), 7.18–8.57 (m, 8H, Ar-H), 9.01 (br s, 1H, NH,  $\text{D}_2\text{O}$  exchangeable). MS  $m/z$  (%): 355  $[\text{M} + 1]^+$  (5), 354  $[\text{M}]^+$  (25), 205 (35), 159 (40), 93 (100), 77(70). Anal. Calcd. for  $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_3\text{S}$  (354.42): C, 64.39; H, 5.12; N, 7.90; S, 9.05. Found: C, 64.26; H, 5.03; N, 7.78; S, 9.14.

### 3.1.3. Reaction of Thioamide Derivatives **4** with $\alpha$ -Halo Carbonyl Compounds: General Procedure for the Preparation of **9a–c**

*Method A:* To a solution of the thioamide derivatives **4a** and **4b** (1 mmol) and 1 mmol of chloroacetone **6** or phenacyl chloride **7** in EtOH (10 mL), 0.2 mL of triethylamine were added. The reaction mixture was refluxed for 10–15 h and then allowed to cool. The solid product obtained was filtered off, washed with EtOH, dried, and finally recrystallized from the proper solvent to afford the corresponding thiophenes **9a–c**, respectively.



By the same method, **4a** (1 mmol) was reacted with 3-chloroacetyl acetone (1 mmol) to afford **9a**, which is identical in all respects (mp, TLC and spectra) in comparison with an authentic sample that obtained from the reaction of **4a** and chloroacetone.

*Method B:* To a mixture of the thioamide derivatives **4a,b** (1 mmol) and chloroacetone **6** or phenacyl chloride **7** (1 mmol) in DMF (5 mL), 0.19 g potassium carbonate was added. The reaction mixture was stirred at ambient temperature for 10 h, and then poured onto ice cold water acidified with 1N HCl. The solid product obtained was filtered off, washed with water, dried and finally recrystallized from the proper solvent to afford products identical in all respect with compounds **9a–d**.

(2-Acetyl-5-phenylimino)thiophen[*c,f*]benzo[7]anulene **9a**. Yield: (0.29 g, 87%); mp: 187–190 °C; buff powder (MeOH). IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  3430 (NH), 1691(C=O).  $^1\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  1.72 (m, 2H,  $\text{CH}_2$ ), 2.15–2.64 (m, 4H, 2 $\text{CH}_2$ ), 2.80 (s, 3H,  $\text{CH}_3$ ), 6.97–7.59 (m, 9H, Ar-H), 8.60 (s, 1H, NH,  $\text{D}_2\text{O}$  exchangeable). MS  $m/z$  (%): 334 [ $\text{M} + 1$ ] $^+$  (7), 333 [ $\text{M}$ ] $^+$  (35), 308 (50), 293 (15), 194 (20), 118 (100), 92 (15), 77 (40). Anal. Calcd. for  $\text{C}_{21}\text{H}_{19}\text{NOS}$  (333.45): C, 75.64; H, 5.74; N, 4.20; S, 9.62. Found: C, 75.32; H, 5.61; N, 4.05; S, 9.74.

(2-Acetyl-5-phenylimino)thiophen[*c,f*]-3-nitrobenzo[7]anulene **9b**. Yield: (0.30 g, 80%); mp: 200–202 °C; yellow crystals (EtOH). IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  3428 (NH), 1654 (C=O).  $^1\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  1.72 (m, 2H,  $\text{CH}_2$ ), 2.35–2.591 (m, 4H, 2 $\text{CH}_2$ ), 3.30 (s, 3H,  $\text{CH}_3$ ), 6.68–8.72 (m, 8H, Ar-H), 9.53 (s, 1H, NH,  $\text{D}_2\text{O}$  exchangeable).  $^{13}\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  21.35, 28.23, 34.12, 39.45, 116.30, 119.35, 122.21, 123.10, 125.50, 129.60, 135.90, 136.10, 138.50, 141.33, 143.31, 145.21, 150.13, 187.21. MS  $m/z$  (%): 379 [ $\text{M} + 1$ ] $^+$  (4), 378 [ $\text{M}$ ] $^+$  (25), 343 (10), 258 (40), 212 (100), 200 (35), 142 (70), 91 (65), 77 (60). Anal. Calcd. for  $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_3\text{S}$  (378.44): C, 66.65; H, 4.79; N, 7.40; S, 8.47. Found: C, 66.51; H, 4.73; N, 7.47; S, 8.55.

(2-Benzoyl-5-phenylimino)thiophen[*c,f*]benzo[7]anulene (**9c**). Yield: (0.31 g, 81%); mp: 195–198 °C; yellow powder (EtOH). IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  3425 (NH), 1681 (C=O).  $^1\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  1.82–2.84 (m, 6H, 3 $\text{CH}_2$ ), 6.97–7.59 (m, 14H, Ar-H), 8.60 (s, 1H, NH,  $\text{D}_2\text{O}$  exchangeable). MS  $m/z$  (%): 396 [ $\text{M} + 1$ ] $^+$  (10), 395 [ $\text{M}$ ] $^+$  (45), 303 (25), 293 (15), 199 (30), 115 (100), 92 (77), 77 (40). Anal. Calcd. for  $\text{C}_{26}\text{H}_{21}\text{NOS}$  (395.52): C, 78.95; H, 5.35; N, 3.54; S, 8.11. Found: C, 78.84; H, 5.28; N, 3.62; S, 8.15.

### 3.1.4. Reactions of Thioamide Derivatives **4a,b** with C-Acetyl-*N*-arylhydrazonoyl Chlorides **14a,b** and C-Ethoxycarbonyl-*N*-arylhydrazonoyl chlorides **18a,b**

The reactions of the thioamide derivatives **4a** and **4b** with hydrazonoyl chlorides **14a,b** and/or **18a,b**, were carried out as described above for the synthesis of thiophene derivatives (method A), to afford the corresponding 1,3,4-thiadiazol derivatives **16a–d** and **19a–d**, respectively.

6-(5-Acetyl-3-*p*-tolyl-1,3,4-thiadiazol-2(3H)-ylidene)-6,7,8,9-tetrahydrobenzo[7]annulene-5-one **16a**. Yield: (0.3 g, 79%); mp: 225–227 °C; yellow powder (MeOH/dioxan). IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  1668, 1653 (C=O).  $^1\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  1.57 (m, 2H,  $\text{CH}_2$ ), 2.40–2.46 (m, 4H, 2 $\text{CH}_2$ ), 3.10 (s, 3H,  $\text{CH}_3$ ), 3.43 (s, 3H,  $\text{CH}_3$ ), 7.10–7.50 (m, 8H, Ar-H). MS  $m/z$  (%): 377 [ $\text{M} + 1$ ] $^+$  (9), 376 [ $\text{M}$ ] $^+$  (75), 187 (45), 160 (20), 91 (80), 86 (100). Anal. Calcd. for  $\text{C}_{22}\text{H}_{20}\text{N}_2\text{O}_2\text{S}$  (376.47): C, 70.19; H, 5.35; N, 7.44; S, 8.52. Found: C, 69.98; H, 5.19; N, 7.66; S, 8.47.

6-(5-Acetyl-3-*p*-tolyl-1,3,4-thiadiazol-2(3H)-ylidene)-6,7,8,9-tetrahydro-3-nitrobenzo[7]annulene-5-one **16b**. Yield: (0.38 g, 90%); mp: 260–262 °C; brown crystals (EtOH/dioxan). IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  1690, 1645 (C=O).  $^1\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  1.70 (m, 2H,  $\text{CH}_2$ ), 2.40–2.46 (m, 4H, 2 $\text{CH}_2$ ), 3.10 (s, 3H,  $\text{CH}_3$ ), 3.43 (s, 3H,  $\text{CH}_3$ ), 7.30–7.90 (m, 7H, Ar-H). MS  $m/z$  (%): 423 [ $\text{M} + 2$ ] $^+$  (11), 421 [ $\text{M}$ ] $^+$  (55), 287 (15), 203 (30), 159 (20), 91 (35). Anal. Calcd. For  $\text{C}_{22}\text{H}_{19}\text{N}_3\text{O}_4\text{S}$  (421.47): C, 62.69; H, 4.54; N, 9.97; S, 7.61. Found: C, 62.35; H, 4.39; N, 10.14; S, 7.41.

6-(5-Acetyl-3-(4-fluorophenyl)-1,3,4-thiadiazol-2(3H)-ylidene)-6,7,8,9-tetrahydrobenzo[7]annulene-5-one **16c**. Yield: (0.32 g, 85%); mp: 240–242 °C; gray powder (dioxan). IR (KBr,  $\text{cm}^{-1}$ ):  $\nu$  1671, 1653 (C=O).  $^1\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  1.53 (m, 2H,  $\text{CH}_2$ ), 2.38–2.46 (m, 4H, 2 $\text{CH}_2$ ), 3.43 (s, 3H,  $\text{CH}_3$ ), 6.76–7.40 (m, 8H, Ar-H).  $^{13}\text{H-NMR}$  (DMSO- $d_6$ ):  $\delta$  23.13, 23.80, 25.41, 38.90, 116.44, 117.60, 119.90, 126.23, 128.75,

130.67, 134.28, 136.13, 140.35, 145.24, 151.20, 154.31, 187.23, 195.25. MS  $m/z$  (%): 381 [M + 1]<sup>+</sup> (9), 380 [M]<sup>+</sup> (45), 187 (25), 160 (27), 91 (85), 86 (100). Anal. Calcd. For C<sub>21</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub>S (380.44): C, 66.30; H, 4.50; N, 7.36; S, 8.43. Found: C, 66.11; H, 4.37; N, 7.55; S, 8.64.

6-(5-Acetyl-3-(4-fluorophenyl)-1,3,4-thiadiazol-2(3H)-ylidene)-6,7,8,9-tetrahydro-3-nitrobenzo-[7]annulen-5-one **16d**. Yield: (0.35 g, 87%); mp: 275–277 °C; green crystals (EtOH/DMF). IR (KBr, cm<sup>-1</sup>):  $\nu$  1680, 1655 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  1.57 (m, 2H, CH<sub>2</sub>), 2.03–2.56 (m, 4H, 2CH<sub>2</sub>), 3.43 (s, 3H, CH<sub>3</sub>), 6.76–8.40 (m, 7H, Ar-H). MS  $m/z$  (%): 425 [M]<sup>+</sup> (30), 245 (45), 171 (20), 95 (100), 77 (60). Anal. calcd. for C<sub>21</sub>H<sub>16</sub>N<sub>3</sub>O<sub>4</sub>S (425.43): C, 59.29; H, 3.79; N, 9.88; S, 7.54. Found: C, 59.09; H, 3.67; N, 10.17; S, 7.73.

Ethyl 4,5-Dihydro-5-(5,6-dihydro-9-oxo-5H-benzo[7]annulen-8(7H)-ylidene)-4-phenyl-1,3,4-thiadiazole-2-carboxylate **19a**. Yield: (0.31 g, 79%); mp: 218–220 °C; brown crystals (EtOH/DMF). IR (KBr, cm<sup>-1</sup>):  $\nu$  1718, 1675 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  1.71 (m, 2H, CH<sub>2</sub>), 2.36–2.80 (m, 6H, 3CH<sub>2</sub>), 4.2 (q,  $J$  = 7.1 Hz, 2H, CH<sub>3</sub>), 6.76–7.20 (m, 9H, Ar-H), <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  13.80, 21.35, 23.85, 35.55, 60.25, 116.30, 118.82, 126.62, 128.70, 129.60, 130.60, 133.00, 134.72, 140.40, 141.80, 154.50, 161.12, 178.35. MS  $m/z$  (%): 393 [M + 1]<sup>+</sup> (6), 392 [M]<sup>+</sup> (25), 346 (20), 194 (15), 242 (45), 150 (30), 92 (100), 77 (80), 65 (60). Anal. Calcd. for C<sub>22</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>S (392.47): C, 67.33; H, 5.14; N, 7.14; S, 8.17. Found: C, 67.12; H, 4.98; N, 7.35; S, 8.34.

Ethyl 4,5-Dihydro-5-(6,7-dihydro-2-nitro-9-oxo-5H-benzo[7]annulen-8(9H)-ylidene)-4-phenyl-1,3,4-thiadiazole-2-carboxylate **19b**. Yield: (0.33 g, 75%); mp: 227–229 °C; buff crystals (EtOH/dioxan). IR (KBr, cm<sup>-1</sup>):  $\nu$  1722, 1638 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  1.50 (t,  $J$  = 7.0 Hz, 3H, CH<sub>3</sub>), 1.71–2.91 (m, 6H, 3CH<sub>2</sub>), 4.16 (q,  $J$  = 7.1 Hz, 2H, CH<sub>2</sub>), 6.83–7.49 (m, 8H, Ar-H), <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  21.11, 23.15, 40.33, 46.39, 64.90, 125.44, 127.60, 127.90, 128.23, 128.75, 133.67, 136.28, 139.13, 141.35, 196.24. MS  $m/z$  (%): 438 [M + 1] (6), 437 [M]<sup>+</sup> (30), 392 (20), 364 (15), 288 (35), 203 (50), 125 (100), 77 (60). Anal. Calcd. for C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>O<sub>5</sub>S (437.47): C, 60.40; H, 4.38; N, 9.61; S, 7.33. Found: C, 59.88; H, 4.26; N, 9.85; S, 7.51.

Ethyl 4,5-Dihydro-5-(5,6-dihydro-9-oxo-5H-benzo[7]annulen-8(7H)-ylidene)-4-*p*-tolyl-1,3,4-thiadiazole-2-carboxylate **19c**. Yield: (0.29 g, 71%); mp: 192–195 °C; gray crystals (EtOH/DMF). IR (KBr, cm<sup>-1</sup>):  $\nu$  1715, 1661 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  1.30 (t,  $J$  = 6.9 Hz, 3H, CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.46–2.92 (m, 4H, 2CH<sub>2</sub>), 3.53 (q,  $J$  = 7.1 Hz, 2H, CH<sub>2</sub>), 4.27 (m, 2H, CH<sub>2</sub>), 6.76–7.50 (m, 8H, Ar-H). MS  $m/z$  (%): 407 [M + 1]<sup>+</sup> (4), 406 [M]<sup>+</sup> (15), 333 (25), 315 (100), 242 (45), 158 (30), 91 (50). Anal. calcd. for C<sub>23</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>S (406.50): C, 67.96; H, 5.46; N, 6.89; S, 7.89. Found: C, 67.52; H, 5.28; N, 7.06; S, 8.13.

Ethyl 4,5-Dihydro-5-(6,7-dihydro-3-nitro-9-oxo-5H-benzo[7]annulen-8(9H)-ylidene)-4-*p*-tolyl-1,3,4-thiadiazole-2-carboxylate **19d**. Yield: (0.37 g, 82%); mp: 235–237 °C; pale yellow crystals (EtOH/DMF). IR (KBr, cm<sup>-1</sup>):  $\nu$  1735, 1670 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  1.35 (t,  $J$  = 6.9 Hz, 3H, CH<sub>3</sub>), 1.91–2.61 (m, 6H, 3CH<sub>2</sub>), 3.28 (s, 3H, CH<sub>3</sub>), 4.37 (q,  $J$  = 7.1 Hz, 2H, CH<sub>2</sub>), 7.22–8.28 (m, 7H, Ar-H), <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  13.35, 23.55, 25.90, 26.11, 38.23, 61.25, 116.32, 121.23, 125.75, 126.61, 127.67, 129.22, 135.13, 141.35, 143.43, 148.20, 148.60, 155.62, 162.20, 185.32. MS  $m/z$  (%): 452 [M + 1]<sup>+</sup> (12), 451 [M]<sup>+</sup> (50), 360 (15), 234 (61), 199 (36), 125 (29), 77 (100). Anal. calcd. for C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub>S (451.49): C, 61.01; H, 4.43; N, 9.54; S, 7.10. Found: C, 61.18; H, 4.69; N, 9.31; S, 7.31.

### 3.1.5. General Procedure for the Preparation of Compounds **21a,b**

A mixture of the **1a,b** (5 mmol), mercaptoacetic acid (5 mmol) and *p*-tolunesulfonic acid (PTSA) in dry benzene (50 mL) was refluxed for 72 h and allowed to cool to room temperature then diluted with water (30 mL). The mixture was washed with saturated NaHCO<sub>3</sub> followed by 0.1N HCl solution. The organic layer was separated and dried over anhydrous sodium sulfate, then evaporated under reduced pressure. The solid products were collected by filtration, washed with EtOH, dried and recrystallized from the proper solvent to afford compounds **21a,b**.

3-((*E*)-6,7-Dihydro-5H-benzo[7]annulen-9-ylthio)propanoic acid **21a**. Yield: (0.21 g, 84%); mp: 193–195 °C; White crystals (MeOH). IR (KBr, cm<sup>-1</sup>):  $\nu$  1722 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  1.65 (m, 2H, CH<sub>2</sub>), 1.96

(t,  $J = 6.7$  Hz, 2H, CH<sub>2</sub>), 2.55–3.14 (m, 6H, 3CH<sub>2</sub>), 7.10–7.50 (m, 5H, Ar-H + CH=C), 11.5 (s, 1H, OH). MS  $m/z$  (%): 249 [M + 1]<sup>+</sup> (25), 248 [M]<sup>+</sup> (100), 175 (36), 143 (75). Anal. Calcd. for C<sub>14</sub>H<sub>16</sub>O<sub>2</sub>S (248.34): C, 67.71; H, 6.49; S, 12.91. Found: C, 67.55; H, 6.33; S, 13.17.

3-((*E*)-6,7-Dihydro-3-nitro-5H-benzo[7]annulen-9-ylthio)propanoic acid **21b**. Yield: (0.35 g, 86%); mp: 208–210 °C; pale yellow crystals (EtOH). IR (KBr, cm<sup>-1</sup>):  $\nu$  1735 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  1.65 (m, 2H, CH<sub>2</sub>), 1.69 (t,  $J = 6.9$  Hz, 2H, CH<sub>2</sub>), 2.55–2.90 (m, 4H, 2CH<sub>2</sub>), 3.14 (t,  $J = 7.0$  Hz, 2H, CH<sub>2</sub>), 7.33–8.50 (m, 4H, Ar-H + CH=C), 12.3 (s, 1H, OH). MS  $m/z$  (%): 294[M + 1]<sup>+</sup> (25), 293[M]<sup>+</sup> (100), 220 (70), 188 (40), 143 (36). Anal. Calcd. for C<sub>14</sub>H<sub>15</sub>NO<sub>4</sub>S (293.34): C, 57.32; H, 5.15; N, 4.77; S, 10.93. Found: C, 57.44; H, 5.04; N, 4.87; S, 11.16.

### 3.1.6. General Procedure for the Preparation of Compounds **22a,b**

To a solution of the appropriate mercaptopropanoic acid derivatives **21a,b** in benzene (thiophene free) (100 mL), phosphorus pentoxide (1 mmol) was added. The resulting mixture was refluxed for 72 h and allowed to cool to room temperature then diluted with water (30 mL), and washed with a saturated NaHCO<sub>3</sub> solution, then we separated the water and HCl was added. The solid products that formed were collected by filtration, washed with water, dried, and recrystallized from the ethanol to afford the newly tricyclic compounds **22a,b**.

2,3-Dihydrothiopyran-4-one[*b,f*]-benzo[7]-9,10,11-trihydroannulene **22a**. Yield: (0.20 g, 86%); mp: 210–212 °C; buff powder (EtOH). IR (KBr, cm<sup>-1</sup>):  $\nu$  1695 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  2.05 (m, 2H, CH<sub>2</sub>), 2.26–2.50 (m, 4H, 2CH<sub>2</sub>), 2.80 (m, 2H, CH<sub>2</sub>), 3.41 (m, 2H, CH<sub>2</sub>), 7.01–7.50 (m, 4H, Ar-H). MS  $m/z$  (%): 231 [M + 1]<sup>+</sup> (25), 230 [M]<sup>+</sup> (100), 214 (36), 142 (75). Anal. Calcd. for C<sub>14</sub>H<sub>14</sub>OS (230.33): C, 73.01; H, 6.13; S, 13.92. Found: C, 72.79; H, 5.95; S, 14.26.

2,3-Dihydrothiopyran-4-one[*b,f*]-3-nitrobenzo[7]9,10,11-trihydroannulene **22b**. Yield: (0.23 g, 83%); mp: 227–230 °C; gray crystals (Dioxane). IR (KBr, cm<sup>-1</sup>):  $\nu$  1683 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  2.15–2.70 (m, 6H, 3CH<sub>2</sub>), 3.25 (m, 2H, CH<sub>2</sub>), 4.07 (t,  $J = 7.0$  Hz, 2H, CH<sub>2</sub>), 7.71–8.47 (m, 3H, Ar-H). <sup>13</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  23.50, 25.9, 28.80, 39.20, 38.50, 120.40, 122.50, 123.99, 130.60, 135.55, 145.01, 148.60, 151.7, 198.90. MS  $m/z$  (%): 276 [M + 1]<sup>+</sup> (23), 275 [M]<sup>+</sup> (100), 219 (70), 186 (40), 115 (36), 63 (29). Anal. calcd. for C<sub>14</sub>H<sub>13</sub>NO<sub>3</sub>S (275.32): C, 61.07; H, 4.76; N, 5.09; S, 11.65. Found: C, 60.93; H, 4.63; N, 5.21; S, 11.89.

### 3.1.7. General Procedure for the Preparation of Compounds **24a,b**

A mixture of the compounds **22a** and/or **22b** (2 mmol), mercaptoacetic acid (2 mmol) and PTSA (2 mmol) in dry benzene (100 mL) was refluxed for 24 h and allowed to cool to room temperature. Phosphorus pentoxide (1 mmol) was then added and the resulting mixture was refluxed for additional 5 h and allowed to cool. The mixture was then diluted with water (30 mL), washed by saturated NaHCO<sub>3</sub> and 0.1N HCl. The organic layer was separated and dried over anhydrous sodium sulfate, then evaporated under reduced pressure. The solid products that formed were collected by filtration, washed with water, dried, and recrystallized from the proper solvent to afford compounds **24a,b**.

2,3-Dihydrothiopyrano[3,2-*b*]thiopyran-4(8H)-one[*d,f*]benzo[7]annulene **24a**. Yield: (0.23 g, 86%); mp: 280–282 °C; white crystal (EtOH/Dioxan). IR (KBr, cm<sup>-1</sup>):  $\nu$  1692 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  2.25–2.50 (m, 6H, 3CH<sub>2</sub>), 3.25–3.38 (m, 4H, 2CH<sub>2</sub>), 3.73 (s, 2H, CH<sub>2</sub>), 7.30–7.57 (m, 4H, Ar-H). <sup>13</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  24.1, 24.9, 35.50, 38.40, 38.90, 126.00, 126.7, 128.01, 128.7, 132.0, 135.17, 138.99, 196.03. MS  $m/z$  (%): 301 [M + 1]<sup>+</sup> (23), 300 [M]<sup>+</sup> (100), 211 (50), 142 (35). Anal. calcd. for C<sub>17</sub>H<sub>16</sub>OS<sub>2</sub> (300.44): C, 67.96; H, 5.37; S, 21.35. Found: C, 67.84; H, 5.26; S, 21.66.

2,3-Dihydrothiopyrano[3,2-*b*]thiopyran-4(8H)-one[*d,f*]-3-nitrobenzo[7]annulene **24b**. Yield: (0.31 g, 90%); mp: >300 °C; brown crystals (EtOH/DMF). IR (KBr, cm<sup>-1</sup>):  $\nu$  1698 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  2.30–2.78 (m, 6H, 3CH<sub>2</sub>), 3.27 (t,  $J = 6.4$  Hz, 2H, CH<sub>2</sub>), 3.33 (t,  $J = 6.8$  Hz, 2H, CH<sub>2</sub>), 3.89 (s, 2H, CH<sub>2</sub>), 7.64–8.37 (m, 3H, Ar-H). MS  $m/z$  (%): 346 [M + 1]<sup>+</sup> (19), 345 [M]<sup>+</sup> (100), 299 (15), 257 (40), 209 (20),

60 (25). Anal. Calcd. for C<sub>17</sub>H<sub>15</sub>NO<sub>3</sub>S<sub>2</sub> (345.44): C, 59.11; H, 4.38; N, 4.05; S, 18.56. Found: C, 58.97; H, 4.26; N, 4.15; S, 18.86.

### 3.1.8. General Procedure for the Preparation of Compounds 25a,b

A mixture of the compound 24a and/or 24b (1 mmol) and hydrogen peroxide (2 mmol) was refluxed for 24 h and allowed to cool to room temperature then diluted with water (30 mL). The solid products that formed were collected by filtration, washed with water, dried and recrystallized from the ethanol to afford compounds 25a,b.

*2,3-Dihydro-dioxothiopyrano[3,2-b]dioxothiopyran-4(8H)-one[d,f]benzo[7]anulen 25a*. Yield (0.23 g, 65%); mp: > 300 °C; gray crystals (Dioxan). IR (KBr, cm<sup>-1</sup>):  $\nu$  1689 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  1.76 (m, 2H, CH<sub>2</sub>), 2.15–2.30 (m, 4H, 2CH<sub>2</sub>), 2.63 (s, 2H, CH<sub>2</sub>), 3.27–3.52 (m, 4H, 2CH<sub>2</sub>), 7.01–7.47 (m, 4H, Ar-H). MS *m/z* (%): 366 [M + 2]<sup>+</sup> (3), 364 [M]<sup>+</sup> (25), 246 (30), 142 (70), 115 (100). Anal. Calcd. for C<sub>17</sub>H<sub>16</sub>O<sub>5</sub>S<sub>2</sub> (364.44): C, 56.03; H, 4.43; S, 17.60. Found: C, 55.76; H, 4.28; S, 18.04.

*2,3-Dihydro-dioxothiopyrano[3,2-b]dioxothiopyran-4(8H)-one[d,f]-3-nitrobenzo[7]anulene 25b*. Yield (0.30 g, 75%); mp: > 300 °C; buff crystals (Dioxan). IR (KBr, cm<sup>-1</sup>):  $\nu$  1695 (C=O). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>):  $\delta$  1.90 (m, 2H, CH<sub>2</sub>), 2.15–2.30 (m, 4H, 2CH<sub>2</sub>), 2.53 (s, 2H, CH<sub>2</sub>), 3.27–4.09 (m, 4H, 2CH<sub>2</sub>), 7.71–8.47 (m, 3H, Ar-H). MS *m/z* (%): 410 [M + 1]<sup>+</sup> (10), 409 [M]<sup>+</sup> (100), 289 (15), 187 (40). Anal. Calcd. for C<sub>17</sub>H<sub>15</sub>NO<sub>7</sub>S<sub>2</sub> (409.43): C, 49.87; H, 3.69; N, 3.42; S, 15.66. Found: C, 49.63; H, 3.57; N, 3.52; S, 15.89.

## 3.2. Biological Evaluation

### 3.2.1. Antimicrobial Activity

The ability to inhibit the growth of Gram-positive and Gram-negative bacteria, yeasts and filamentous fungi was observed using an overlay method [17].

#### Sample Preparation

All samples were dissolved in dimethyl sulfoxide (RFCL Limited, New Delhi, India) DMSO at 10 mg/mL concentration as shown in the Table 1 in comparison with different standard antibiotics. Antibiotic discs of Streptomycin (S) (10 µg), Oxytetracycline (T) (30 µg) and Tetracycline (TE) (30 µg) were used as positive controls for bacteria. Neomycin (N) (30 µg), was used for fungi. The experiment was performed in triplicate.

#### Strains and Media Used

The common pathogenic and food spoilage microorganisms were selected for their relevance in bakery products and other food: the gram-positive bacteria; *Bacillus subtilis* NRRL-B-4219, *Staphylococcus aureus* ATCC 6538, *Enterococcus faecalis* ATCC 19433 and the gram negative bacteria; *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 9027, *Proteus* sp., yeasts such as *Candida albicans* ATCC 10231, fungi *Aspergillus niger* NRRL 2766 (equivalent to ATCC16888), and *Aspergillus flavus* ATCC 16883.

The bacteria were slanted on nutrient agar (Merck, Darmstadt, Germany), Yeast was slanted and mentioned on Sabaroud's agar medium (Lab M., Bury, Lancashire, UK) and the fungi was slanted and mentioned on the potato Dextrose Agar medium (Lab M Limited, Bury, Lancashire, UK). Mueller-Hinton agar (Lab M., Bury, Lancashire, UK) following the manufacturer's instructions was used for the assay.

#### Bioassay

The antibacterial screening was essentially by the well diffusion agar method [23,24]. The organisms were streaked in radial patterns on the agar plates. Plates were incubated under aerobic conditions at 37 °C and 28 °C for 24 h and 48 h for bacteria and fungi, respectively. In order to

obtain comparable results, all prepared solutions were treated under the same conditions under the same incubated plates. All tests were performed in triplicate. Plates were examined for evidence of antimicrobial activities, represented by a zone of inhibition of the microorganism's growth around the holes, and diameters of clear zones were expressed in millimeters [25].

### 3.2.2. Determination of Minimum Inhibitory Concentration (MIC)

The *in vitro* minimum inhibitory concentration (MIC) of the synthesized compounds was determined by the agar well diffusion method. DMSO was used to prepare different concentrations ranging from 50 to 500 µg/mL by serial dilutions. The media were inoculated with 100 µL of each of the 10<sup>6</sup> cfu/mL bacterial and fungal strains, and the assay was applied by an agar well diffusion method. Blank DMSO was used as negative control. The plates were incubated aerobically in an incubator at 37 °C for 24 h for bacterial strains and 25 °C for 48 h for fungal strains. The MIC was taken as the lowest concentration in the series dilution that prevented bacterial growth.

## 4. Conclusions

An efficient one step method for the synthesis of substituted thiophene derivatives **9** from thioamides **4** and  $\alpha$ -haloketones has been performed. Reaction of **4** with C-acetyl-*N*-arylhydrazonoyl chlorides **14** and C-ethoxycarbonyl-*N*-arylhydrazonoyl chlorides **18** under basic conditions, afforded the corresponding 1,3,4-thiadiazoline derivatives **16** and **19**, respectively. Benzosuberones **1** underwent condensation followed by cyclization to obtain tricyclic thiopyran-4(5*H*)-one derivatives and tetracyclic ring systems **24** and **25**. The newly synthesized compounds showed to be active when tested as antimicrobial agents.

**Acknowledgments:** The project was financially supported by King Saud University, Vice Deanship of Research Chairs.

**Author Contributions:** The listed authors contributed to this work as described in the following. Osama I. Abd El-Salam, Aly S. Alsayed, Korany A. Ali, Abd El-Galil E. Amr gave the concepts of the work, interpreted the results and prepared the manuscript, Ahmed A. Abd Elwahab carried out the experimental part (this work is a part of his PhD thesis) and Hassan M. Awad tested the antimicrobial activities. All authors have read and approved the final manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Rida, S.M.; Habib, N.S.; Badawey, E.A.; Fahmy, H.T.; Ghozlan, H.A. Synthesis of novel thiazolo[4,5-*d*]pyrimidine derivatives for antimicrobial, anti-HIV and anticancer investigation. *Pharmazie* **1996**, *51*, 927–931. [[CrossRef](#)] [[PubMed](#)]
2. Bahashwan, S.A.; Fayed, A.A.; Ramadan, M.A.; Amr, A.E.; Al-Harbi, N.O. Androgen receptor antagonists and anti-prostate cancer activities of some newly synthesized substituted fused pyrazolo-, triazolo- and thiazolo-pyrimidine derivatives. *Int. J. Mol. Sci.* **2014**, *15*, 21587–21602. [[CrossRef](#)] [[PubMed](#)]
3. Abou-Ghalia, M.H.; Amr, A.E. Synthesis and investigation of a new cyclo-(*N*<sup>α</sup>-ipicolinoyl) pentapeptide of a breast and CNS cytotoxic activity and an ionophoric specificity. *Amino Acids* **2004**, *26*, 283–289.
4. Yadagiri, B.; Holagunda, U.D.; Bantu, R.; Nagarapu, L.; Kumar, C.G.; Pombala, S.; Sridhar, B. Synthesis of novel building blocks of benzosuberone bearing coumarin moieties and their evaluation as potential anticancer agents. *Eur. J. Med. Chem.* **2014**, *79*, 260–265. [[CrossRef](#)] [[PubMed](#)]
5. Nagarapu, L.; Yadagiri, B.; Bantu, R.; Kumar, G.; Pombala, S.; Nanubolu, J. Studies on the synthetic and structural aspects of benzosuberones bearing 2,4-thiazolidenone moiety as potential anti-cancer agents. *Eur. J. Med. Chem.* **2014**, *71*, 91–97. [[CrossRef](#)] [[PubMed](#)]
6. Tatsumi, M.; Groshan, K.; Blakely, R.D.; Richelson, E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. *Eur. J. Pharmacol.* **1997**, *340*, 249–258. [[CrossRef](#)]
7. Mutschler, E. *Drug Actions: Basic Principles and Therapeutic Aspects*; ISBN: 0-8493-7774-9; Medpharm Scientific Pub.: Stuttgart, Germany, 1995; p. 127. Retrieved 30 January 2013.

8. Rostom, S.A.F.; El-Ashmawy, I.M.; Abd El Razik, H.A.; Badr, M.H.; Ashour, M.A. Design and synthesis of some thiazolyl and thiadiazolyl derivatives of antipyrine as potential non-acidic anti-inflammatory, analgesic and antimicrobial agents. *Bioorg. Med. Chem.* **2009**, *17*, 882–895. [[CrossRef](#)] [[PubMed](#)]
9. Ali, A.M.; Saber, G.E.; Mahfouz, N.M.; El-Gendy, M.A.; Radwan, A.A.; Hamid, M.A. Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors. *Arch. Pharm. Res.* **2007**, *30*, 1186–1204. [[CrossRef](#)] [[PubMed](#)]
10. Ouf, N.H.; Amr, A.E.; Sakran, M.I. Anticancer activity of some newly synthesized pyrano[2,3-*d*][1,2,3] triazine derivatives using 1-(7-hydroxy-2,2-dimethylchroman-6-yl)ethanone as synthon. *Med. Chem. Res.* **2015**, *24*, 1514–1526. [[CrossRef](#)]
11. Abd El-Salam, O.I.; Abou El-Ella, D.A.; Ismail, N.S.M.; Abdullah, M. Synthesis, docking studies and anti-inflammatory activity of some 2-amino-5,6,7,8-tetrahydroquinoline-3-carbonitriles and related compounds. *Pharmazie* **2009**, *64*, 147–155. [[PubMed](#)]
12. Abdel Salam, O.I.; Khalifa, N.M.; Said, S.A.; Amr, A.E. Synthesis and antimicrobial activities of some newly 2,4,6-tri-substituted pyridine derivatives. *Res. Chem. Intermed.* **2014**, *40*, 1147–1155. [[CrossRef](#)]
13. Amr, A.E.; Abd El-Salam, O.I.; Al-Omar, M.A. Synthesis of Chiral Macrocycles: I. Synthesis and Study of Cyclo(*N*<sup>α</sup>-Dinicotinoyl)pentapeptide Candidates. *Russ. J. Gen. Chem.* **2015**, *85*, 1161–1166. [[CrossRef](#)]
14. Amr, A.E.; Ali, K.A.; Abdalla, M.M. Cytotoxic, antioxidant activities and structure activity relationship of some newly synthesized terpenoidaloxaliplatin analogs. *Eur. J. Med. Chem.* **2009**, *44*, 901–907. [[CrossRef](#)] [[PubMed](#)]
15. Ali, K.A.; Abdalghfar, H.S.; Mahmoud, K.; Ragab, E.A. Synthesis and antitumor activity of new poly-substituted thiophenes and 1,3,4-thiadiazoles incorporating 2,6-pyridine moieties. *J. Heterocycl. Chem.* **2013**, *50*, 1157–1164.
16. Ali, K.A.; Hosni, H.M.; Elngar, D.H.; Amr, A.E. Synthesis and reactions of 2-(phenylthiocarbamoyl)-*N*-(benzothiazol-2-yl)-3-phenyl-3-oxopropanamide with activated chloro-compounds. *Phosphorus Sulfur Silicon* **2014**, *189*, 1831–1840. [[CrossRef](#)]
17. Connell, S.R.; Tracz, D.M.; Nierhaus, K.H.; Taylor, D.E. Ribosomal protection proteins and their mechanism of tetracycline resistance. *Antimicrob. Agents Chemother.* **2003**, *47*, 3675–3681. [[CrossRef](#)] [[PubMed](#)]
18. Hinman, M.M.; Rosenberg, T.A.; Balli, D.; Black-Schaefer, C.; Chovan, L.E.; Kalvin, D.; Merta, P.J.; Nilius, A.M.; Pratt, S.D.; Soni, N.B.; *et al.* Novel antibacterial class: A series of tetracyclic derivatives. *J. Med. Chem.* **2006**, *49*, 4842–4856. [[CrossRef](#)] [[PubMed](#)]
19. Smith, P.A.S.; Berry, W.L. Some Exploratory Syntheses of Benzosuberans and Tetrahydrobenzazepinones and Some Related Diazoöxides. *J. Org. Chem.* **1961**, *26*, 27–36. [[CrossRef](#)]
20. Amr, A.E.; Mohamed, A.M.; Mohamed, S.F.; Abdel-Hafez, N.A.; Hammam, A.G. Anticancer activities of some newly synthesized pyridine, pyrane, and pyrimidine derivatives. *Bioorg. Med. Chem.* **2006**, *14*, 5481–5488. [[CrossRef](#)] [[PubMed](#)]
21. Dieckmann, W.; Platz, L. Ueber eineneue Bildungs weise von Osotetrazonen. *Chem. Ber.* **1905**, *38*, 2986–2990. [[CrossRef](#)]
22. Shawali, A.S.; Albar, H.A. Kinetics and mechanism of dehydrochlorination of *N*-aryl-*C*-ethoxycarbonylformohydrazidoyl chlorides. *Can. J. Chem.* **1986**, *64*, 871–875. [[CrossRef](#)]
23. Williams, S.T.; Goodfellow, M.; Wellington, E.M.H.; Vickers, J.C.; Alderson, G.; Sneath, P.H.A.; Sackins, S.M.J.; Mortimer, A.M. A Probability Matrix for Identification of some Streptomycetes. *J. Gen. Microbiol.* **1983**, *129*, 1815–1830. [[CrossRef](#)] [[PubMed](#)]
24. Bonev, B.; Hooper, J.; Parisot, J. Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method. *J. Antimicrob. Chemother.* **2008**, *61*, 1295–1301. [[CrossRef](#)] [[PubMed](#)]
25. Cruickshank, R.; Duguid, J.P.; Marmion, B.P.; Swain, R.H.A. The practice of medicinal microbiology. In *Medical Microbiology*, 12th ed.; Churchill Livingstone: Edinburgh, UK, 1975; Volume 11, pp. 196–202.

**Sample Availability:** Samples of the compounds are not available from the authors.



© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).